Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
Avraham Frisch1, Shlomzion Aumann2, Tsila Zuckerman1
1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Abstract:
Remission assessment in acute myeloid leukemia has evolved over the recent years with the advent of molecular and flow-based minimal residual disease determination. Nonetheless, early time point such as day 5 and day 14 (D14), still have prognostic and therapeutic implications. D14 refractory disease is regarded as a poor prognostic factor, however the therapeutic intervention is still under debate, with evidence suggesting a successful re-induction might offer similar long-term outcome as D14 aplasia. Others advocate the use of more intensive salvage protocols as a mean to overcome the negative prognostic effect. In the current study, we compare outcome of D14 refractory AML patients treated with either re-induction or salvage protocol. More importantly, we identify response characteristics that might suggest which patients will benefit from re-induction approach. Accurate identification of chemotherapy refractory patients might allow the early incorporation of non-chemotherapy based protocols in the future.
Insights
Early assessment of acute myeloid leukemia (AML) is crucial. This study compares re-induction versus salvage therapy for Day 14 refractory AML, identifying patients who benefit most from re-induction.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) has advanced with molecular and flow cytometry techniques.
- Early time points, such as Day 14 (D14), remain critical for prognosis and treatment decisions in AML.
- Refractory disease at D14 is a poor prognostic indicator, but optimal therapeutic strategies are debated.
Purpose of the Study:
- To compare the outcomes of D14 refractory AML patients treated with either re-induction or salvage protocols.
- To identify specific patient characteristics that predict benefit from a re-induction approach.
- To inform future treatment strategies for chemotherapy-refractory AML.
Main Methods:
- Retrospective analysis comparing outcomes in D14 refractory AML patients.
- Patients were stratified based on treatment received: re-induction chemotherapy or intensive salvage protocols.
- Analysis of response characteristics to identify predictors of successful re-induction.
Main Results:
- Outcomes were compared between patients receiving re-induction versus salvage therapy for D14 refractory AML.
- Key response characteristics were identified that may indicate suitability for re-induction.
- The study aims to provide evidence to guide therapeutic choices for this high-risk AML subgroup.
Conclusions:
- The choice between re-induction and salvage therapy for D14 refractory AML impacts patient outcomes.
- Identifying patients likely to benefit from re-induction can optimize treatment and potentially improve long-term survival.
- Accurate identification of chemotherapy refractory disease may facilitate earlier integration of non-chemotherapy based treatments.
